Global Hematologic Malignancies Treatment Market Share

Statistics for the 2023 & 2024 Global Hematologic Malignancies Treatment market share, created by Mordor Intelligence™ Industry Reports. Global Hematologic Malignancies Treatment share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Market Share of Global Hematologic Malignancies Treatment Industry

The hematologic malignancies treatment market is moderately consolidated and consists of several major players. Some of the companies currently dominating the market include Pfizer Inc., F. Hoffmann-LA Roche Ltd, Sanofi SA, Bristol-Myers Squibb Company, AbbVie Inc., Novartis AG, GlaxoSmithKline PLC, Amgen Inc., Johnson & Johnson, and Takeda Pharmaceutical Co. Ltd. Most of the major players are focusing on expanding their businesses in the developing regions to boost their market shares. They are implementing strategies like mergers and acquisitions and new product developments. For instance, in August 2020, GlaxoSmithKline PLC received US FDA approval for its BLENREP (belantamab mafodotin-blmf), a first-in-class anti-BCMA (B-cell maturation antigen) therapy for the treatment of patients with relapsed or refractory multiple myeloma.

Hematologic Malignancies Treatment Market Leaders

  1. Pfizer, Inc.

  2. F. Hoffmann-LA Roche ltd

  3. AbbVie, Inc.

  4. Bristol-Myers Squibb Company

  5. Sanofi S.A

*Disclaimer: Major Players sorted in no particular order

Pfizer Inc., F. Hoffmann-LA Roche Ltd, Sanofi SA, Bristol-Myers Squibb Company,  AbbVie Inc., Novartis AG, GlaxoSmithKline PLC, Amgen Inc., Takeda Pharmaceutical Co. Ltd,  Johnson & Johnson

Hematologic Malignancies Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)